TAT Antibody (H-9): sc-376292

TAT Antibody (H-9) is a mouse monoclonal IgG2a kappa light chain antibody that detects TAT protein of mouse, rat, and human origin by western blotting (WB), immunoprecipitation (IP), immunofluorescence (IF), immunohistochemistry, and enzyme-linked immunosorbent assay (ELISA). TAT (H-9) antibody is available in both non-conjugated and various conjugated forms, including agarose, horseradish peroxidase (HRP), phycoerythrin (PE), fluorescein isothiocyanate (FITC), and multiple Alexa Fluor® conjugates. TAT protein, or tyrosine aminotransferase, is a crucial 454 amino acid enzyme that resides in the mitochondria and is a member of the class-I pyridoxal-phosphate-dependent aminotransferase family. TAT protein functions as a homodimer and utilizes pyridoxal phosphate as a cofactor to facilitate the conversion of L-tyrosine into p-hydroxyphenylpyruvate, a vital step in amino acid degradation. Defects in the TAT gene can lead to tyrosinemia type 2 (TYRO2), a metabolic disorder characterized by elevated tyrosine levels in the blood and urine, along with symptoms such as palmoplantar keratosis, painful corneal ulcers, and cognitive impairments. The TAT gene is located on human chromosome 16, which is home to over 900 genes and constitutes nearly 3% of the human genome, highlighting the significance of TAT in both metabolic pathways and genetic health.

Alexa Fluor^® is a trademark of Molecular Probes Inc., OR., USA

LI-COR^® and Odyssey^® are registered trademarks of LI-COR Biosciences

TAT Antibody (H-9) References:

1. Point mutations in the tyrosine aminotransferase gene in tyrosinemia type II.  |  Natt, E., et al. 1992. Proc Natl Acad Sci U S A. 89: 9297-301. PMID: 1357662
2. Tyrosine aminotransferase and gamma-glutamyl transferase activity in human fetal hepatocyte primary cultures under proliferative conditions.  |  Rehman, KK., et al. 2004. Cell Biochem Funct. 22: 89-96. PMID: 15027097
3. Clinical and mutational investigations of tyrosinemia type II in Northern Tunisia: identification and structural characterization of two novel TAT mutations.  |  Charfeddine, C., et al. 2006. Mol Genet Metab. 88: 184-91. PMID: 16574453
4. TAT gene mutation analysis in three Palestinian kindreds with oculocutaneous tyrosinaemia type II; characterization of a silent exonic transversion that causes complete missplicing by exon 11 skipping.  |  Maydan, G., et al. 2006. J Inherit Metab Dis. 29: 620-6. PMID: 16917729
5. Identification of two new mutations in the TAT gene in a Danish family with tyrosinaemia type II.  |  Pasternack, SM., et al. 2009. Br J Dermatol. 160: 704-6. PMID: 18945316
6. Isolation and characterization of the human tyrosine aminotransferase gene.  |  Rettenmeier, R., et al. 1990. Nucleic Acids Res. 18: 3853-61. PMID: 1973834
7. Superinduction of tyrosine aminotransferase by actinomycin D in rat hepatoma (HTC) cells.  |  Thompson, EB., et al. 1970. J Mol Biol. 54: 159-75. PMID: 4395444
8. Stimulation of tyrosine aminotransferase synthesis by dexamethasone phosphate in cell culture.  |  Granner, DK., et al. 1968. J Mol Biol. 35: 291-301. PMID: 4398833
9. Expression of aryl hydrocarbon hydroxylase induction and suppression of tyrosine aminotransferase induction in somatic-cell hybrids.  |  Benedict, WF., et al. 1972. Proc Natl Acad Sci U S A. 69: 2179-83. PMID: 4403306
10. Mechanism of hormonal induction of tyrosine aminotransferase studied by measurement of the concentration of growing enzyme molecules.  |  Scott, WA., et al. 1972. Proc Natl Acad Sci U S A. 69: 2937-41. PMID: 4404146
11. Induction of cytosolic tyrosine aminotransferase by dexamethasone in organ culture of fetal human liver.  |  Andersson, SM. 1982. Early Hum Dev. 6: 165-9. PMID: 6124417
12. Novel and recurrent tyrosine aminotransferase gene mutations in tyrosinemia type II.  |  Hühn, R., et al. 1998. Hum Genet. 102: 305-13. PMID: 9544843

Monoclonal antibodies for mammalian and non-mammalian protein targets represent essentially all targets covered by polyclonal antibodies. Over 8,300 of our antibodies are offered as ImmunoCruz^® conjugates which eliminates the need for a secondary antibody.

Santa Cruz Biotechnology antibodies have over 360,000 research citations. Anti-TAT Antibody (H-9) has 5 citations in a variety of scientific publications.

Primary antibodies like Anti-TAT Antibody (H-9) for mammalian target proteins are recommended for the detection of a range of mammalian species, primarily of mouse, rat and human species. Many mammalian antibodies are also ideal for veterinary research and reactive with ovine, porcine, caprine, feline, canine, bovine and equine protein targets. Santa Cruz Biotechnology primary monoclonal antibodies are suitable for laboratory research applications and are not intended for diagnostic or therapeutic use.

TAT Antibody (H-9) Specifications

Alternate Product Name: TAT

Product Clone Name: H-9

Classification: Primary Antibody

Clonality: Monoclonal Antibody

Antibody Isotype: IgG_2a kappa light chain

Amino Acids: 99-127

Epitope Target: TAT

Epitope Species: human

Product Reactivity/Detection: TAT

Species Reactivity/Detection: mouse, rat, human

Additional Mammalian Reactivity: N/A

Additional Non-Mammalian Reactivity: N/A

Applications: WB, IP, IF, IHC(P), ELISA

Vialing Information: Each vial contains 200 µg IgG_2a kappa light chain in 1.0 ml of PBS with < 0.1% sodium azide and 0.1% gelatin

Research Citations: 5 citations in various scientific publications

Available Conjugates/Forms for TAT Antibody (H-9): AC: Agarose, AF488: Alexa Fluor^® 488, AF546: Alexa Fluor^® 546, AF594: Alexa Fluor^® 594, AF647: Alexa Fluor^® 647, AF680: Alexa Fluor^® 680, AF790: Alexa Fluor^® 790, FITC: Fluoroscein, HRP: Horseradish Peroxidase, P: Blocking Peptide, PE: Phycoerythrin